Colin joined Shell International in Den Haag and served in NW Borneo and other group operating companies including Shell UK. He held executive positions with the French group TOTAL S.A in strategic planning & development economics and at ExxonMobil where he was a member of Management Council, Vice President and Director overseeing the business, scientific and technical service directorates at Mobil Gas Marketing and Mobil North Sea.
After the Millennium he worked extensively in the UK public service and third sectors, across local government, environment, justice, education and health. He was also appointed Chief Executive at the Chief Fire Officers Association and Presidential Advisor to the ministerial steering board, pivotal roles under the Bain reform of the UK Fire & Rescue Service; also Chief Executive at the national mutual & hospital group Benenden Healthcare. He was there a director delegate member of the Association Internationale de la Mutualité, an international umbrella organisation of not-for-profit healthcare federations procuring or providing medical coverage to around 240 million people across Europe, Latin America, Africa and the Middle East; also Chief Executive at the National Open College Network, a leading UK and international qualifications ‘Awarding Organisation’ overseeing essential vocational learning, apprenticeship development and core functional skills.
He advised on modernising the Environment Agency under UK Treasury, Office of Government Commence programme to leverage international treaty objectives for air, water and ground quality through the introduction of enabling technology. He was formerly Chair at the Atlantic Margin Joint Industry Group covering sensitive marine waters from the Barents Sea through to the Atlantic west of Greenland through its subsidiary the Atlantic Frontier Environmental Network that focussed on monitoring the seabed, cetaceans, seabirds, and coastal protection for responsible access.
Colin is an Oxford Martin Visiting Fellow on the ‘Affordable Medicines’ programme with the University of Oxford, through support of the SGC, Structural Genomics Consortium based at the university’s Nuffield Department of Clinical Medicine. He also appointed Alan Tayler Advisory Fellow (Mathematics) by the University of Oxford where in addition he is advisor to the directors of the joint EPSRC Centre for Doctoral Training, industrially focused mathematical modelling programme at the Mathematics Institute.
He has led successful small business start-ups in publishing, medicine and tourism. Colin has been a guest lecturer in Engineering at the University of Aberdeen and led an inaugural post graduate external mentorship programme at the Kuala Lumpur Business School, University of Nottingham Malaysia Campus.
Colin holds other board positions as a trustee at the Shakespeare Birthplace Trust first incorporated by an Act of Parliament in 1891 to promote in every part of the world the appreciation and study of the plays and to preserve Shakespearian properties and a museum standard collection of writings and other associated national treasures. He is also a trustee at the Wallacea Trust that works on international community conservation and biodiversity, focussed around worldwide scientific data collection and expedition sites of Operation Wallacea.
James is the founder and CEO of EnteroBiotix, leading the company from its inception to where it is today.
James holds a BMedSci (Hons) in Physiology from the University of Edinburgh and is currently a final year medical student at the University of Aberdeen. He was named ‘Young Pioneer of the Year’ by Herald Scotland and was named as one of the ‘Ten Outstanding Young Persons in Scotland’ by Junior Chamber International. He is also a Fellow of the Royal Society of the Arts.
James was the first medical student to be awarded an Enterprise Fellowship by the Royal Society of Edinburgh and was recently awarded a Visiting Research Fellowship by United European Gastroenterology. He has strong academic interests and has been published as first author in journals such as Alimentary Pharmacology & Therapeutics.
Lewis Ritchie has been James Mackenzie Professor of General Practice at the University of Aberdeen since 1992 and is former Director of Public Health, NHS Grampian. He holds Chemistry and Medical Degrees from the University of Aberdeen and a Degree in Community Medicine from the University of Edinburgh. He previously served as a GP Principal at Peterhead Health Centre & Community Hospital. He has also served NHS Grampian in the past as Consultant/Honorary Consultant in Public Health Medicine.
He has contributed to the NHS in Scotland in a number of capacities, including as member or chair of national advisory committees to the Scottish Government. He presently chairs the Scottish Medical and Scientific Advisory Committee (SMASAC), the Prescription for Excellence Steering Board and has recently been asked to lead a review of out-of-hours primary care services in Scotland. He was recently appointed to be the next Chairman of the Queen’s Nursing Institute Scotland.
His research and development interests include: cardiovascular prevention, immunisation, ehealth/telecare and development of new models of prevention and healthcare delivery. He has published a number of reports and wrote the book: Computers in Primary Care. He has a particular interest in promoting clinical professionalism and leadership within the health service.
He has received a number of professional awards for his contributions, including the Fellowship and Perry Prize of the British Computer Society, for his work on cardiovascular prevention. In 2001, he was appointed OBE for services to primary care and was subsequently knighted in 2011 for services to the NHS in Scotland.
Andrew is an investor and advisor in new technology ventures, applying thirty years’ experience in IT, business development, strategy and partnerships. His most recent venture was sold to Capita plc in 2015.
Andrew’s career includes senior international roles as European principal of a technology investment advisory group, director of partnerships for BT New Ventures and head of technical strategy, alliances and partnerships for Fujitsu, living and working in USA, Europe and Australia.
Previously Andrew consulted in IT strategy, running a national practice; taught Information Management at Napier University Business School, launching a new degree course; and started his career developing financial software having taught himself programming as a teenager.
Andrew holds a first class honours degree from the University of Leicester and a Masters in Computational Theory from the University of Edinburgh. He maintains a keen interest in science and has published in computing and game theory.
Andrew is currently chairman of FinFire, a specialist FinTech advisory firm. He is also a member of Equity Gap, the Scottish business angel syndicate, and a mentor for Edinburgh Research and Innovation Ltd, the commercialisation arm of Edinburgh University.
Gavin is a native Scot and a Chemistry graduate of the University of Strathclyde (1978) with 38 years of experience in the biopharmaceutical industry. After a brief spell as a chemist at Ethicon (J&J), Gavin moved into the commercial arena with positions at Janssen, Bayer and Novartis. Between 1994-99 he was responsible for Global Infectious Diseases Licensing at GlaxoWellcome and thereafter VP Business Development at Belgium based Tibotec Pharmaceuticals. In the former role, Gavin closed eight major licensing deals with global partners from Japan, Asia Pacific, Europe and USA and in the latter, was responsible for business development at Tibotec until its acquisition by Johnson & Johnson in 2002.
In 2009 he co-founded and was Chief Business Officer at Glasgow based MGB Biopharma Limited, the company which licensed Strathclyde Professor Colin Suckling’s novel DNA Minor Groove Binder Technology from the University.
Gavin is active in his consulting company in the UK, Marlin Bioconsulting Ltd and has consulted in a variety of commercial roles and has worked on a number of fundraising, Mergers & Acquisitions and Licensing deals for his client base in the US, Asia Pacific and the EU. He is Non-Executive Director at Lamellar Biomedical Ltd, representing the investment interests there of Scottish Enterprise. He is a Certified Licensing Professional (CLP), as accredited by the Licensing Executives Society North America. In addition, Gavin is on the advisory board at the Scottish Lifesciences Advisory board and is an active Enterprise partner and mentor of at the Business School at University of Strathclyde.
James Clark brings executive management level experience at the nexus of the therapeutic and diagnostic industries, specialising in Companion Diagnostics (CDx) and Next Generation Sequencing (NGS). During his career he has worked extensively in therapeutics and molecular oncology, developing and commercialising over 10 diagnostic products. He was formerly Chief Technical Officer at Enterome Bioscience, a microbiome company pioneering the development of novel pharmaceuticals and diagnostics to support personalised therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD), cancer and metabolic diseases.
James brings US-based CLIA lab experience having held executive roles in a number of oncology companies including VP Research and Development at MDx Health and COO at Response Genetics.
He holds a BSc in Microbiology and obtained his PhD from the Biochemistry Department of Glasgow University.